marked.bio

WRN helicase inhibitor · small molecule

VVD-133214

2 active trials, targeting WRN. Not approved for any biomarker on marked.bio yet.

Also known as RO7589831.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 2 2 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of VVD-133214.

  1. Bayer 2

Trials

2 of 2 trials shown

  1. A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

    Recruiting Phase 2 Bayer Started 2026Primary completion 2028-06 NCT07811193

    VVD-133214pembrolizumab FDA EU

    Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard o…

    MSI-H / dMMRColorectal Adenocarcinoma

  2. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Bayer Started 2024Primary completion 2027-05 NCT06004245

    VVD-133214pembrolizumab FDA EUbevacizumab

    Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented…

    MSI-H / dMMRAdvanced Solid Tumors, Colorectal Cancer